Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Berinert Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy 1011-14

    Berinert Coverage for Acute Hereditary Angioedema Attacks

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy 1011-14 alerts

    Get alerted when Policy 1011-14 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and notification requirements for Berinert for adult and pediatric members with hereditary angioedema. Coverage is limited to treatment of acute attacks and excludes combination use with other products indicated for acute hereditary angioedema attacks.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyBerinert Coverage for Acute Hereditary Angioedema Attacks
    Policy CodePolicy 1011-14
    Change TypeAnnual review
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization or notification and document hereditary angioedema, an acute attack, and no concurrent acute-attack therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The annual review updated the examples of therapies used for acute hereditary angioedema attacks.

    12 monthsAuthorization duration
    3Required coverage criteria
    Adult and pediatricEligible populations
    Acute attacksCovered purpose

    Berinert Coverage Criteria

    Berinert Coverage Criteria

    Berinert will be approved when ALL of the following criteria are met:

    All Berinert coverage criteria

    • Diagnosis of hereditary angioedema (HAE): The member has a diagnosis of hereditary angioedema (HAE).
    • Treatment of acute HAE attacks: Berinert is used for the treatment of acute HAE attacks.
    • No combination therapy: Berinert is not used in combination with other products indicated for acute HAE attacks, such as Ekterly, Firazyr, Kalbitor, or Ruconest.

    Coverage of Berinert requires that it is not used in combination with another product indicated for treatment of acute hereditary angioedema attacks, including Ekterly, Firazyr, Kalbitor, or Ruconest.

    Prophylactic use of Berinert is not covered because the safety and efficacy of Berinert for prophylactic therapy have not been established.

    Authorization and Denial Considerations

    Prior Authorization

    Obtain prior authorization or notification for Berinert

    Prior authorization or notification applies to Berinert. Approval requires a diagnosis of hereditary angioedema, treatment of an acute hereditary angioedema attack, and no concurrent use of another product indicated for acute hereditary angioedema attacks.

    Denial Risk

    Avoid noncovered use and combination therapy

    Coverage may be denied when Berinert is not being used to treat an acute hereditary angioedema attack or when it is used in combination with another product indicated for acute hereditary angioedema attacks.

    • Combination products include Ekterly, Firazyr, Kalbitor, or Ruconest.
    • Prophylactic use is not covered because the safety and efficacy of Berinert for prophylactic therapy have not been established.
    Denial Risk

    Confirm a hereditary angioedema diagnosis

    Coverage may be denied when the member does not have a diagnosis of hereditary angioedema (HAE). Document the HAE diagnosis when requesting Berinert approval.

    Clinical Background

    Berinert is a plasma-derived C1 esterase inhibitor indicated for treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema in adult and pediatric patients. Its safety and efficacy for prophylactic therapy have not been established.

    Key Terms

    Berinert
    ProductBerinert
    DefinitionA plasma-derived C1 esterase inhibitor (human).
    UseIndicated for treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema in adult and pediatric patients.
    Acute hereditary angioedema attack
    DefinitionAn acute attack associated with hereditary angioedema (HAE).
    Attack locationsAbdominal, facial, or laryngeal.
    Affected populationsAdult and pediatric patients.

    Initial Berinert Approval

    Initial Berinert Approval

    Initial approval requires ALL of the following:

    All initial approval criteria

    • Diagnosis of hereditary angioedema (HAE): The member has a diagnosis of hereditary angioedema (HAE).
    • Treatment of acute HAE attacks: Berinert is used for the treatment of acute HAE attacks.
    • No combination therapy: Berinert is not used in combination with other products indicated for acute HAE attacks, including Ekterly, Firazyr, Kalbitor, or Ruconest.
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyBerinert Coverage for Acute Hereditary Angioedema Attacks
    Policy CodePolicy 1011-14
    Change TypeAnnual review
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization or notification and document hereditary angioedema, an acute attack, and no concurrent acute-attack therapy.
    SourceLink
    On This Page
    Berinert Coverage CriteriaAuthorization and Denial ConsiderationsClinical BackgroundKey TermsInitial Berinert Approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.